Steris price target raised to $265 from $255 at KeyBanc

KeyBanc analyst Brett Fishbin raised the firm’s price target on Steris to $265 from $255 on valuation, while keeping an Overweight rating on the shares. Last week, the firm hosted meetings with management, and walked away “incrementally comfortable” with the setup for 2025 as well as its ability to realize long-term financial objectives over the next several years. More specifically, despite some investor skepticism, it remained confident in the full-year outlook, KeyBanc says.